AZN.L Shariah Compliance
Screening Methodology: AAOIFI
LOCKED
AstraZeneca PLC. Stock Analysis AZN
United States Health Care Large Cap AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company discovers, develops, and commercializes prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal and metabolism, respiratory and immunology and vaccines and immune therapies. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex, Faslodex and others. Its rare diseases products include Soliris, Ultomiris, Strensiq and Kanuma. Its biopharmaceuticals products include Farxiga, Crestor, Breztri and others. Its investigational vaccine candidate IVX-A12, which targets both respiratory syncytial virus and human metapneumovirus. Its oncology candidate includes FPI-2265 targeting prostate specific membrane antigen for metastatic castration resistant prostate cancer, which is in a Phase II trial. The company also discovers, develops, and manufactures T-cell receptor therapies. Its Eneboparatide is an investigational therapeutic peptide.
Read More AZN Chart
AstraZeneca PLC vs FTSE 100 Comparative Returns
Analysis of AZN stock performance compared to the broader market (FTSE 100) across multiple timeframes.
YTD Performance
- AstraZeneca PLC... (AZN...) 2.72%
- FTSE 100 4.83%
AstraZeneca PLC Underperformed FTSE 100 by 2.11%
1Y Performance
- AstraZeneca PLC... (AZN...) -12.56%
- FTSE 100 3.86%
AstraZeneca PLC Underperformed FTSE 100 by 16.42%
3Y Performance
- AstraZeneca PLC... (AZN...) 7.54%
- FTSE 100 15.8%
AstraZeneca PLC Underperformed FTSE 100 by 8.26%
5Y Performance
- AstraZeneca PLC... (AZN...) 26.29%
- FTSE 100 45.73%
AstraZeneca PLC Underperformed FTSE 100 by 19.44%
Key Statistics
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$68.04Volume
7.15MP/E Ratio (TTM)
22.3152 Week Range
Market Cap
181.48BAvg. Volume
5.96MDividend Yield
2.95%Financial Metrics & Statements
- Per Share Data
- Ratios
- Statements
| Currency: USD | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
Revenue per Share (TTM) | 20.28 | 24.15 | 28.62 | 29.55 | - |
EBIT per Share (TTM) | 3.35 | 3.16 | 5.7 | 5.75 | - |
Dividend per Share (TTM) | 2.72 | 2.49 | 2.82 | 2.89 | - |
EPS Forward | - | - | 2.11 | 3.81 | 4.5 |
Super Investors
Super Investors are top-performing investors known for their exceptional market strategies and long-term success in wealth creation.
George Soros
% Portfolio:
3.61 Recent Activity:18.96%
Ken Fisher
% Portfolio:
0.29 Recent Activity:4.58%
Ron Baron
% Portfolio:
0.02 Recent Activity:-19.21%
Dodge & Cox
% Portfolio:
< 0.01 Recent Activity:-3.57%
Community-Curated Collections ( With AZN )
View AllCommunity-Curated Collections are thoughtfully selected groups of stocks or assets, curated by investors and experts based on shared themes, values, or investment strategies.
FAQ's
Halal stocks refer to shares of companies that comply with Islamic finance principles, meaning they do not engage in businesses related to alcohol, gambling, pork, or interest-based financial services.
Alternate Halal Stocks
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
